SP
Swisscanto Private Equity
Swisscanto Private Equity is a Series B to Series C stage investment firm. It has made 8 investments. Average disclosed round size is $32.7M (across 6 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Unknown
Last 12 Mo
0
Team
RS
Robert Schier
Investment Director
AN
Andreas Nicoli
Head
SV
Sebastien Valdemar Marang
Private Equity
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 ANYbotics | Series C | $60M | Dec 2024 |
| MMemo Therapeutics AG | Series C | — | May 2024 |
 NIL Technology | Unknown | — | May 2024 |
| ANYbotics | Series B | $60M | Jan 2024 |
| MMemo Therapeutics AG | Series C | — | Nov 2023 |
 Medimaps Group | Unknown | $20M | Jan 2021 |
 tado° | Series B | $17.1M | Oct 2015 |
 Nagi Bioscience | Unknown | — | — |
 MediMaps | Unknown | $20M | — |
 MedTrace Pharma | Unknown | $19M | — |
| MMemo Therapeutics AG | Series B | — | — |
Top Co-Investors
Verve Ventures7 shared
Swisscom Ventures4 shared
NGP Capital3 shared
Zürcher Kantonalbank2 shared
Schroders Capital2 shared
Vesalius Biocapital2 shared
British International Investment2 shared
Redalpine2 shared
Pureos Bioventures2 shared
Idinvest Partners2 shared
Qualcomm Ventures2 shared
Supernova Invest2 shared
TDK Ventures2 shared
Walden Catalyst Ventures2 shared
Bessemer Venture Partners2 shared
imec.xpand1 shared
Excellis1 shared
Ysios Capital1 shared
Kurma Partners1 shared
Credit Suisse Group AG1 shared
Last updated: 20 October 2026